Genocea Provides Fourth Quarter 2021 Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- S&P Global explores potential separation of Capital IQ business
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Genocea Biosciences (GNCA) Tops Q4 EPS by 1c
March 10, 2022 7:01 AM ESTGenocea Biosciences (NASDAQ: GNCA) reported Q4 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20).
Genoceas existing cash is sufficient to support our current operations into Q3 2022, however we have strategic plans to extend our operations into 2023.
For earnings history and earnings-related data on Genocea Biosciences (GNCA) click here.
... More


